Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
- 94 Downloads
PET/CT using 68Ga-labeled somatostatin analogs (SSA) targeting somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) represents the clinical reference standard for imaging. However, economic and logistic challenges of the 68Ge/68Ga generator-based approach have disadvantages over 18F-labeled compounds. Here, we present the first in-human data of 18F-SiFAlin-TATE, a novel 18F-labeled, SSR-targeting peptide. The aim was to compare the intra-individual biodistribution, tumor uptake, and image quality of 18F-SiFAlin-TATE to the clinical reference standard 68Ga-DOTA-TOC.
Thirteen patients with NET staged with both 68Ga-DOTA-TOC and 18F-SiFAlin-TATE PET/CT have been included in this retrospective analysis. We compared the biodistribution in normal organs and tumor uptake of NET lesions by SUVmean and SUVmax measurement for tracers. Additionally mean and max tumor-to-liver (TLR) and tumor-to-spleen ratios (TSR) have been calculated by division of SUVmean and SUVmax of tumor lesions by the SUVmean of the liver and spleen, respectively. Additionally, image quality was visually rated by 5 blinded readers and an intra-class correlation (ICC) analysis on inter-observer agreement has been performed.
Compared with 68Ga-DOTA-TOC, the biodistribution of 18F-SiFAlin-TATE showed somewhat higher, however, statistically not significant higher uptake in the liver, spleen, and adrenal glands. Significantly higher uptake was observed in the kidneys. Tumor uptake was higher in most tumor lesions with significantly higher uptake in common metastatic sites of NET including the liver (SUVmax 18.8 ± 8.4 vs. 12.8 ± 5.6; p < 0.001), lymph nodes (SUVmax 23.8 ± 20.7 vs. 17.4 ± 16.1; p < 0.001) and bone (SUVmax 16.0 ± 10.1 vs. 10.3 ± 5.7; p < 0.01) for 18F-SiFAlin-TATE. The high tumor uptake resulted in favorable TLR and TSR, comparable with that of 68Ga-DOTA-TOC. The ICC analysis on the inter-observer agreement on image quality was substantial and almost perfect. Image quality was rated as excellent in most cases in both 68Ga-DOTA-TOC and 18F-SiFAlin-TATE PET.
The favorable characteristics of 18F-SiFAlin-TATE with a high image quality, the kit-like labeling procedure, and the promising clinical performance enable improved logistics and diagnostic possibilities for PET imaging of NET. Our first clinical results warrant further systematic studies investigating the clinical use of 18F-SiFAlin-TATE in NET patients.
KeywordsNET PET/CT imaging Somatostatin receptor imaging 68Ga-DOTA-TOC 18F-SiFAlin-TATE 18F labeling
Compliance with ethical standards
Conflict of interest
HI is an advisory board member of Bayer, received research funding from Novartis and speaker honoraria from Bayer and Ipsen. CA received research contracts from Ipsen, Novartis, and ITM Solucin; lecture honoraria from Ipsen, Novartis, and Falk Foundation; and advisory board honoraria from Novartis. CS received research grants from Novartis; lecture honoraria from Ipsen and Novartis; and advisory board honoraria from Ipsen, Novartis, and Pfizer. All other authors declare no competing interests.
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent was obtained from all individual participants included in the study.
- 3.Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601. https://doi.org/10.1007/s00259-017-3728-y.CrossRefGoogle Scholar
- 6.Niedermoser S, Chin J, Wangler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In vivo evaluation of (1)(8)F-SiFAlin-modified TATE: a potential challenge for (6)(8)Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med. 2015;56:1100–5. https://doi.org/10.2967/jnumed.114.149583.CrossRefGoogle Scholar
- 7.Wangler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, et al. One-step (1)(8)F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem. 2010;21:2289–96. https://doi.org/10.1021/bc100316c.CrossRefGoogle Scholar
- 9.General Assembly of the World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–8.Google Scholar
- 10.Revy A, Hallouard F, Joyeux-Klamber S, Skanjeti A, Rioufol C, Fraysse M. Feasibility and evaluation of automated methods for radiolabeling of radiopharmaceutical kits with gallium-68. Curr Radiopharm. 2019. https://doi.org/10.2174/1874471012666190110170623.
- 11.Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)in-pentetreotide scintigraphy vs. (68)Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.118.223016.
- 16.Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23. https://doi.org/10.1007/s00259-012-2309-3.CrossRefGoogle Scholar
- 17.Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04455-9.
- 20.Aalbersberg EA, de Wit-van der Veen BJ, MWJ V, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46:696–703. https://doi.org/10.1007/s00259-018-4117-x.CrossRefGoogle Scholar
- 21.Galne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenstrom E, et al. A prospective observational study to evaluate the effects of long-acting somatostatin analogs on (68)Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.226332.
- 22.Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, et al. Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:677–85. https://doi.org/10.1007/s00259-018-4193-y.CrossRefGoogle Scholar